Core Capital Management & Research inc. Takes Position in Pfizer Inc. $PFE

Key Points

• Core Capital Management & Research initiated a Pfizer position in the second quarter, purchasing 194,623 shares worth approximately $4.7 million. Pfizer represented 2.5% of the fund’s portfolio, while institutional investors collectively owned 68.36% of the stock.
• Analyst sentiment remains cautious: Pfizer has an overall “Hold” rating and an average price target of $28.28, with 14 Holds, four Buys, one Strong Buy and two Sell ratings.
• Pfizer exceeded quarterly expectations with earnings of $0.77 per share and revenue of $15.03 billion, but its $1.72 annual dividend implies a high 6.2% yield and a payout ratio above 226%.

Core Capital Management & Research inc. bought a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The fund bought 194,623 shares of the biopharmaceutical company's stock, valued at approximately $4,687,000. Pfizer accounts for 2.5% of Core Capital Management & Research inc.'s investment portfolio, making the stock its 15th largest holding.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Handelsbanken Fonder AB raised its stake in shares of Pfizer by 10.4% during the 2nd quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company's stock worth $59,295,000 after buying an additional 232,528 shares during the period. Russell Investments Group Ltd. grew its stake in Pfizer by 15.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company's stock valued at $132,365,000 after acquiring an additional 745,213 shares during the period. Leuthold Group LLC acquired a new stake in Pfizer in the 2nd quarter valued at $4,887,000. North Dakota State Investment Board purchased a new stake in Pfizer in the 4th quarter worth $5,348,000. Finally, Park National Corp OH raised its position in Pfizer by 332.1% during the second quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company's stock worth $5,829,000 after acquiring an additional 186,053 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PFE. Weiss Ratings upgraded shares of Pfizer from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday, August 31st. Wolfe Research restated an "underperform" rating and set a $26.00 price target on shares of Pfizer in a research report on Thursday, May 14th. Bank of America decreased their price target on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a research note on Friday, July 10th. Wall Street Zen cut Pfizer from a "buy" rating to a "hold" rating in a report on Saturday, September 5th. Finally, Royal Bank Of Canada raised Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 target price for the company in a report on Tuesday, June 9th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $28.28.

Pfizer Price Performance

Pfizer stock opened at $27.82 on Thursday. Pfizer Inc. has a 52-week low of $23.58 and a 52-week high of $29.21. The firm has a market capitalization of $158.58 billion, a price-to-earnings ratio of 36.61, a PEG ratio of 1.87 and a beta of 0.34. The company has a fifty day simple moving average of $26.21 and a 200-day simple moving average of $26.35. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company's revenue for the quarter was up 2.6% on a year-over-year basis. During the same period last year, the firm posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.2%. The ex-dividend date was Friday, July 24th. Pfizer's payout ratio is currently 226.32%.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s latest quarterly results exceeded expectations, with adjusted earnings of $0.77 per share versus the $0.68 consensus and revenue of $15.03 billion versus estimates of $14.40 billion. The results helped revive the stock after a prolonged downturn and reinforced management’s full-year 2026 EPS guidance of $2.80-$3.00. Why Pfizer Stock Was so Healthy in August
• Positive Sentiment: Analysts point to Pfizer’s non-COVID portfolio, oncology pipeline and cost-cutting initiatives as potential growth and margin supports. These factors could help offset falling COVID product sales and extend the company’s recovery. Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit?
• Neutral Sentiment: Pfizer will present at the Morgan Stanley Global Healthcare Conference on September 14. Chief Executive Albert Bourla’s comments could provide updates on the pipeline, capital allocation and the company’s strategy for managing patent losses. Pfizer Invites Public to Listen to Webcast
• Neutral Sentiment: Novartis India agreed to acquire Pfizer brands for $132 million, including an established hypertension product. The transaction may generate cash and streamline Pfizer’s portfolio, but its financial impact appears limited relative to Pfizer’s roughly $159 billion market value. Novartis India Acquires Pfizer Brands
• Negative Sentiment: Jim Cramer selected Johnson & Johnson over Pfizer among healthcare stocks, a high-profile preference that may weigh on Pfizer’s relative appeal. Another comparison favored AbbVie as a stronger dividend-growth investment, despite Pfizer’s roughly 6% yield. Jim Cramer Picks J&J Over Pfizer

Pfizer Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer's products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.